Kite Pharma Inc. (NASDAQ:KITE)‘s stock had its “buy” rating reissued by Jefferies Group in a research note issued to investors on Wednesday.

The analysts wrote, “Recently, a debate has arisen over pot’l Zuma-1 efficacy differences across autologous stem cell transplant (ASCT)-relapsed and refractory pts due to semantics around the word relapsed”. We believe little distinction has been given to the ASCT-relapsed group within the larger relapsed population with the perception that ASCT-relapsed pts are healthier than refractory pts.””

Several other brokerages have also weighed in on KITE. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $70.00 target price on shares of Kite Pharma in a research report on Monday, October 10th. Vetr lowered Kite Pharma from a “strong-buy” rating to a “buy” rating and set a $63.91 target price on the stock. in a research report on Tuesday, September 13th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $74.00 target price on shares of Kite Pharma in a research report on Thursday, September 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Kite Pharma in a research report on Sunday, October 9th. Finally, Barclays PLC increased their target price on Kite Pharma from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 27th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $71.57.

Analyst Recommendations for Kite Pharma (NASDAQ:KITE)

Shares of Kite Pharma (NASDAQ:KITE) opened at 51.69 on Wednesday. The stock’s market capitalization is $2.58 billion. Kite Pharma has a 52-week low of $38.41 and a 52-week high of $87.50. The company has a 50 day moving average of $49.15 and a 200 day moving average of $52.34.

Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.63) by $0.14. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%. The firm had revenue of $7.34 million for the quarter, compared to analysts’ expectations of $4.94 million. During the same period last year, the business posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 43.1% on a year-over-year basis. Analysts predict that Kite Pharma will post ($5.52) EPS for the current fiscal year.

In related news, COO Cynthia M. Butitta sold 10,000 shares of the stock in a transaction on Monday, September 26th. The stock was sold at an average price of $54.13, for a total value of $541,300.00. Following the completion of the transaction, the chief operating officer now owns 105,477 shares in the company, valued at approximately $5,709,470.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey Wiezorek sold 1,500 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $54.81, for a total value of $82,215.00. Following the completion of the transaction, the senior vice president now owns 17,311 shares of the company’s stock, valued at approximately $948,815.91. The disclosure for this sale can be found here. 20.60% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in Kite Pharma during the second quarter worth $120,000. Picton Mahoney Asset Management bought a new position in Kite Pharma during the second quarter worth $135,000. BNP Paribas Arbitrage SA raised its position in Kite Pharma by 115.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,301 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 1,768 shares during the period. Howard Hughes Medical Institute raised its position in Kite Pharma by 11.3% in the second quarter. Howard Hughes Medical Institute now owns 3,431 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 348 shares during the period. Finally, BlackRock Inc. raised its position in Kite Pharma by 91.9% in the second quarter. BlackRock Inc. now owns 4,022 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,926 shares during the period. Institutional investors and hedge funds own 75.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Kite Pharma Inc. (KITE) Stock Rating Reaffirmed by Jefferies Group” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/23/kite-pharma-inc-kite-stock-rating-reaffirmed-by-jefferies-group-2.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

5 Day Chart for NASDAQ:KITE

Receive News & Stock Ratings for Kite Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc. and related stocks with our FREE daily email newsletter.